Journal article
Cancer and Inflammation: Promise for Biologic Therapy
Journal of immunotherapy (1997), Vol.33(4), pp.335-351
05/01/2010
DOI: 10.1097/CJI.0b013e3181d32e74
PMCID: PMC2941912
PMID: 20386472
Abstract
Cancers often arise as the end stage of inflammation in adults, but not in children. As such there is a complex interplay between host immune cells during neoplastic development, with both an ability to promote cancer and limit or eliminate it, most often complicit with the host. In humans, defining inflammation and the presence of inflammatory cells within or surrounding the tumor is a critical aspect of modern pathology. Groups defining staging for neoplasms are strongly encouraged to assess and incorporate measures of the presence of apoptosis, autophagy, and necrosis and also the nature and quality of the immune infiltrate. Both environmental and genetic factors enhance the risk of cigarette smoking, Helicobacter pylori, hepatitis B/C, human papilloma virus, solar irradiation, asbestos, pancreatitis, or other causes of chronic inflammation. Identifying suitable genetic polymorphisms in cytokines, cytokine receptors, and Toll-like receptors among other immune response genes is also seen as high value as genomic sequencing becomes less expensive. Animal models that incorporate and assess not only the genetic anlagen but also the inflammatory cells and the presence of microbial pathogens and damage-associated molecular pattern molecules are necessary. Identifying micro-RNAs involved in regulating the response to damage or injury are seen as highly promising. Although no therapeutic strategies to prevent or treat cancers based on insights into inflammatory pathways are currently approved for the common epithelial malignancies, there remains substantial interest in agents targeting COX2 or PPAR gamma, ethyl pyruvate and steroids, and several novel agents on the horizon.
Details
- Title: Subtitle
- Cancer and Inflammation: Promise for Biologic Therapy
- Creators
- Sandra Demaria - New York UniversityEli Pikarsky - Hadassah Medical CenterMichael Karin - University of California San DiegoLisa M. Coussens - University of California, San FranciscoYen-Ching Chen - National Taiwan UniversityEmad M. El-Omar - University of AberdeenGiorgio Trinchieri - National Institutes of HealthSteven M. Dubinett - David Geffen School of Medicine at UCLAJenny T. Mao - New Mexico VA Health Care SystemEva Szabo - National Institutes of HealthArthur Krieg - Pfizer, Cambridge, MA USAGeorge J. Weiner - University of IowaBernard A. FoxGeorge Coukos - National Institutes of HealthEna Wang - National Institutes of HealthRobert T. Abraham - Pfizer,Michele Carbone - University of PittsburghMichael T. Lotze - University of Pittsburgh
- Resource Type
- Journal article
- Publication Details
- Journal of immunotherapy (1997), Vol.33(4), pp.335-351
- DOI
- 10.1097/CJI.0b013e3181d32e74
- PMID
- 20386472
- PMCID
- PMC2941912
- NLM abbreviation
- J Immunother
- ISSN
- 1524-9557
- eISSN
- 1537-4513
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 17
- Grant note
- Pfizer 1 P01 CA 101944-04 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA M01RR000056 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) P30CA047904 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) ZIACL002118 / CLINICAL CENTER
- Language
- English
- Date published
- 05/01/2010
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359942902771
Metrics
22 Record Views